文献速递乳腺癌

Nectin-4:一种有效靶向原发性和转移性三阴性乳腺癌的新预后生物标志物

Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer.
PubMed 文献 · Ann Oncol · 2017-01-01

该研究在5673例浸润性乳腺癌中分析Nectin-4/PVRL4 mRNA表达与临床病理特征及无转移生存(MFS)的相关性,并在61例三阴性乳腺癌(TNBC)及患者来源异种移植(PDX)中验证蛋白表达。高PVRL4 mRNA表达在TNBC多因素分析中对MFS显示独立负面预后价值,62%的TNBC存在膜蛋白表达。研究者构建的抗Nectin-4抗体药物偶联物(ADC)N41mab-vcMMAE在体外和体内对Nectin-4阳性TNBC(包括原发瘤、转移灶和局部复发)诱导快速、完全且持久的应答。

要点

  • 高Nectin-4/PVRL4 mRNA表达与TN和基底亚型等不良预后特征相关。
  • TNBC多因素分析中高PVRL4 mRNA对MFS显示独立负面预后价值。
  • 62%的TNBC存在Nectin-4膜蛋白表达,与mRNA表达强相关。

核心结论

  • Nectin-4既是新的有前景的预后生物标志物,也是TNBC有限治疗武器库中ADC的特异性治疗靶点。

研究设计与样本

  • 研究分析了5673例浸润性乳腺癌的Nectin-4/PVRL4 mRNA表达,并寻找其与包括无转移生存(MFS)在内的临床病理特征的相关性。
  • 对61例TNBC及原发TNBC患者来源异种移植(PDX)样本进行免疫组化检测。
  • 制备了可用于ADC的抗Nectin-4抗体,并在局部和转移性TNBC PDX中进行体外和体内测试。

主要发现

  • 高Nectin-4/PVRL4 mRNA表达与包括TN和基底亚型在内的不良预后特征相关。
  • 在TNBC多因素分析中,高PVRL4 mRNA表达对MFS显示独立负面预后价值。
  • 在包括乳腺组织在内的成人健康组织中未检测到Nectin-4蛋白表达。
  • 62%的TNBC中发现膜蛋白表达,与mRNA表达强相关。
  • ADC N41mab-vcMMAE在体外以高亲和力和特异性结合Nectin-4,诱导其内化并对表达Nectin-4的乳腺癌细胞系产生剂量依赖性细胞毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Triple-negative breast cancers (TNBCs) are associated with a poor prognosis. In contrast to other molecular subtypes, they have no identified specific target and chemotherapy remains the only available systemic treatment. The adhesion molecule nectin-4 represents a new potential therapeutic target in different cancer models. Here, we have tested the prognostic value of nectin-4 expression and assessed the therapeutic efficiency of an anti-nectin 4 antibody drug conjugate (ADC) on localised and metastatic TNBC in vitro and in vivo. MATERIALS AND METHODS: We analysed nectin-4/PVRL4 mRNA expression in 5673 invasive breast cancers and searched for correlations with clinicopathological features including metastasis-free survival (MFS). Immunohistochemistry was carried out in 61 TNBCs and in samples of primary TNBC Patient-Derived Xenografts (PDXs). An anti-nectin-4 antibody eligible for ADC was produced and tested in vitro and in vivo in localised and metastatic TNBC PDXs. RESULTS: High nectin-4/PVRL4 mRNA expression was associated with poor-prognosis features including the TN and basal subtypes. High PVRL4 mRNA expression showed independent negative prognostic value for MFS in multivariate analysis in TNBCs. Nectin-4 protein expression was not detected in adult healthy tissues including mammary tissue. Membranous protein expression was found in 62% of TNBCs, with strong correlation with mRNA expression. We developed an ADC (N41mab-vcMMAE) comprising a human anti-nectin-4 monoclonal antibody conjugated to monomethyl auristatin-E (MMAE). In vitro, this ADC bound to nectin-4 with high affinity and specificity and induced its internalisation as well as dose-dependent cytotoxicity on nectin-4-expressing breast cancer cell lines. In vivo, this ADC induced rapid, complete and durable responses on nectin-4-positive xenograft TNBC samples including primary tumours, metastatic lesions, and local relapses; efficiency was dependent on both the dose and the nectin-4 tumour expression level. CONCLUSION: Nectin-4 is both a new promising prognostic biomarker and specific therapeutic target for ADC in the very limited armamentarium against TNBC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. M-Rabet M, Cabaud O, Josselin E, et al. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Ann Oncol. 2017. PMID: 27998973. doi:10.1093/annonc/mdw678

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。